Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer - Madrigal Pharmaceuticals (NASDAQ:MDGL)

CONSHOHOCKEN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today

Related Keywords

Julian Baker ,Sanofi Genzyme ,Alex Howarth ,Paul Friedman ,Lycera Corp ,Avanir Pharmaceuticals ,Sanofi Executive Committee ,Harvard Business School ,Yale University ,Madrigal Pharmaceuticals Inc ,Madrigal Pharmaceuticals ,Exchange Commission ,Bill Sibold ,Chief Executive Officer ,Executive Vice President ,Specialty Care ,Sanofi North America ,Rare Disease ,Rare Blood Disorders ,Sanofi Executive ,Sanofi Specialty Care ,Global Business ,Senior Vice President ,Global Franchise Head ,Multiple Sclerosis ,Global Franchise Head Multiple ,Chief Commercial Officer ,Molecular Biophysics ,Harvard Business ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,